

1533621

JC20 Rec'd PCT/PTO 29 APR 2005

Practitioner's Docket No. 033393-055184

PATENT

IN THE UNITED STATES RECEIVING OFFICE (RO/US)

PCT/US2003/034424 29 October 2003 29 October 2002
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

INHIBITION OF GENE EXPRESSION USING RNA INTERFERING AGENTS
TITLE OF INVENTION

THE CENTER FOR BLOOD RESEARCH, et al.
APPLICANT(S)

Mail Stop PCT (EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EV653000539US in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: April 29, 2005


Debra J. Kellom

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form 1449/A PTO, for consideration by the Examiner in connection with the examination of the above-identified patent application.

I. REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or

00/533621

JC20 Rec'd PCT/PTO 29 APR 2005

— (4) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

X A copy of the International Search Report is enclosed herewith.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):


X are enclosed herewith; and
— have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments relative to the submission should be credited to said Deposit Account.

Respectfully submitted,



David S. Resnick (Reg. 34,235)
Leena H. Karttunen (37 C.F.R. §10.9(b))
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110
(617) 345-6057/1367

Date: April 29, 2005

JC20 Rec'd PCI/PTO 29 APR 2005

Substitute for form I449A/PTO				<i>Complete if Known</i> 10/533621	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	To be assigned
				Filing Date	Herewith
				First Named Inventor	Lieberman et al.
				Art Unit	
				Examiner Name	To be assigned
				Attorney Docket Number	033393-055184
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

JC20 Rec'd PCT/PTO 29 APR 2005

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	To be assigned
				Filing Date	Here with
				First Named Inventor	Lieberman, et al.
				Group Art Unit	
				Examiner Name	To be assigned
Sheet	2	of	2	Attorney Docket Number	033393-055184

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	MARTINEZ, et al. Supression of Chemokine Receptor Expression by RNA Interference Allows for Inhibition of HIV-1 Replication. AIDS, 2002, Vol. 16, pages 2385-2390.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.